Q2 EPS Estimate for Nektar Therapeutics Reduced by Analyst
Nektar Therapeutics (NASDAQ:NKTR – Free Report) – Stock analysts at HC Wainwright decreased their Q2 2025 EPS estimates for shares of Nektar Therapeutics in a note issued to investors on Monday, May 12th. HC Wainwright analyst A. He now expects that the biopharmaceutical company will earn ($0.18) per share for the quarter, down from their […]
Nektar Therapeutics (NASDAQ:NKTR – Free Report) – Stock analysts at HC Wainwright decreased their Q2 2025 EPS estimates for shares of Nektar Therapeutics in a note issued to investors on Monday, May 12th. HC Wainwright analyst A. He now expects that the biopharmaceutical company will earn ($0.18) per share for the quarter, down from their […]
